Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition

Retrieved on: 2025-01-20 13:43:59

Tags for this article:

Click the tags to see associated articles and topics

Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition. View article details on hiswai:

Excerpt

Benitec uses gene silencing technologies to develop therapies, with lead asset BB-301 targeting Oculopharyngeal Muscular Dystrophy in Phase 1b/2a ...

Article found on: seekingalpha.com